Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-
Public Disclosure of Hospital Errors, CANDOR System Get Giant Boost From Medicare/Medicaid
-
CXApp Inc. (Nasdaq: CXAI) Announces Largest “Expansion” Deal & Strategic Multi-Year Agreement with Google Cloud
-
Peraso Announces Second Quarter 2024 Results
-
Restaurant Brands International Inc. Announces Receipt of Exchange Notice, Intent to Use Common Shares to Satisfy Exchange and Commencement of Secondary Offering of Common Shares
-
“I loved going to work when I first started. Now I dread it:” new study on Ontario’s hospital workers’ deteriorating morale to be released on Wednesday in Ottawa
-
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
-
Spectral AI Announces 2024 Second Quarter Financial Results
-
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
-
Bridger Aerospace Announces Second Quarter 2024 Results
-
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
SKYX Reports Record Second Quarter Sales of $21.4 Million Compared to $15.0 Million for Second Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Sma
-
Aspira Women’s Health Reports Second Quarter 2024 Financial Results
-
Viant Technology Announces Second Quarter 2024 Financial Results
-
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
-
AB Announces July 31, 2024 Assets Under Management
-
Vicarious Surgical Reports Second Quarter 2024 Financial Results
-
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
-
Stereotaxis Reports 2024 Second Quarter Financial Results
-
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
-
Procore Announces Investor Call with CRO Larry Stack
-
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
-
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
-
iRobot Names Michael J. Loparco to Board of Directors
-
Fathom Holdings Reports Second Quarter 2024 Results
-
Former Vice Chairman of Bell Canada Wade Oosterman Joins Calix Board of Directors
-
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
-
TherapeuticsMD Announces Second Quarter 2024 Financial Results
-
Rogers Corporation Announces Departure of Chief Financial Officer
-
Virtus Investment Partners Reports Preliminary July 31, 2024 Assets Under Management
-
Cardea Successfully Closes $15 Million Convertible Note Financing
-
Brenmiller Energy Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
-
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
-
Feinstein Institutes Dr. Stephanie L. Fitzpatrick Named President, Society for Health Psychology of the American Psychological Association
-
GeneDx to Participate in Fall Investor Conferences
-
Archrock, Inc. Announces Tender Offer for Outstanding Notes
-
Ameresco and the City of Somersworth Break Ground on New Hampshire’s First Landfill Solar Project to be Placed on a Superfund Site
-
GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event
-
Werner Enterprises Announces Quarterly Dividend
-
TeraWulf Reports Second Quarter 2024 Financial Results
-
Rumble Reports Second Quarter 2024 Results
-
Cibus to Participate in Upcoming August Investor Events
-
Biora Therapeutics Announces Funding Agreement with Existing Investors
-
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Stronghold Digital Mining Sets Second Quarter 2024 Earnings Conference Call for Wednesday, August 14 at 11:00 a.m. Eastern Time
-
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
-
Firefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024
-
Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
-
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
-
Exodus Reports Second Quarter 2024 Results
